Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Exanthema × ruxolitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 13 Myeloproliferative Disorders 10 Polycythemia Vera 9 Leukemia, Myeloid, Acute 7 Graft vs Host Disease 5 Thrombocythemia, Essential 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Myelodysplastic Syndromes 4 Leukemia 4 Hematologic Neoplasms 4 Myelodysplastic-Myeloproliferative Diseases 3 Breast Neoplasms 3 Recurrence 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Monocytic, Acute 2 Hodgkin Disease 2 Carcinoma, Non-Small-Cell Lung 2 Burkitt Lymphoma 2 Bronchiolitis Obliterans Syndrome 2 Triple Negative Breast Neoplasms 1 Targeted Therapy 1 Squamous Cell Carcinoma of Head and Neck 1 Relapsed Pediatric Solid Tumor 1 Prostatic Neoplasms 1

Interventions

Fulvestrant 2 ruxolitinib 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Sirolimus 1 Prednisone 1 Panitumumab 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Gels 1 Doxycycline 1 Dapsone 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06399029 2025-11-19

TRUX-LST

University of Zurich

Phase 2 Recruiting

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡